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Abstract
Millions of people worldwide are currently infected with human papillomavirus (HPV), herpes simplex virus (HSV) or human
immunodeficiency virus (HIV). For this enormous contingent of people, the search for preventive and therapeutic
immunological approaches represents a hope for the eradication of latent infection and/or virus-associated cancer. To date,
attempts to develop vaccines against these viruses have been mainly based on a monovalent concept, in which one or
more antigens of a virus are incorporated into a vaccine formulation. In the present report, we designed and tested an
immunization strategy based on DNA vaccines that simultaneously encode antigens for HIV, HSV and HPV. With this
purpose in mind, we tested two bicistronic DNA vaccines (pIRES I and pIRES II) that encode the HPV-16 oncoprotein E7 and
the HIV protein p24 both genetically fused to the HSV-1 gD envelope protein. Mice i.m. immunized with the DNA vaccines
mounted antigen-specific CD8+ T cell responses, including in vivo cytotoxic responses, against the three antigens. Under
experimental conditions, the vaccines conferred protective immunity against challenges with a vaccinia virus expressing the
HIV-derived protein Gag, an HSV-1 virus strain and implantation of tumor cells expressing the HPV-16 oncoproteins.
Altogether, our results show that the concept of a trivalent HIV, HSV, and HPV vaccine capable to induce CD8+ T cell-
dependent responses is feasible and may aid in the development of preventive and/or therapeutic approaches for the
control of diseases associated with these viruses.
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Introduction
The diseases caused by human immunodeficiency virus (HIV),
human papillomavirus (HPV) and herpes simplex virus (HSV)
represent serious public health threats, as they affect millions of
people irrespective of economic or social status [1]. The mortality
and morbidity associated with HIV or HSV infection were
significantly reduced after the discovery and dissemination of anti-
viral therapies that reduce viral loads and relieve symptoms in
infected people. However, the currently available drugs are not
able to eradicate the viruses, and infections with these viruses
remain in a chronic latent state and recur after treatment
interruption (HIV) or after debilitation of the immune defenses
(HSV). Despite decades of intense scientific work and enormous
investments, no effective anti-HIV or anti-HSV vaccine is
presently available [2]. Regarding HPV, two prophylactic vaccines
that are able to induce antibody responses have been shown to
confer protection against virus infection and therefore reduce the
long-term incidence of HPV-associated tumors [3,4]. However,
the impact on the incidence of HPV-associated cancers is expected
to be observed only after the widespread use of these vaccines.
Nonetheless, those already infected with high-risk HPV types or
afflicted with HPV-associated cancer or neoplastic lesions are not
expected to benefit from preventive anti-viral vaccines. Therefore,
the development of therapeutic cancer vaccines that target HPV-
infected cells is a priority for several research groups [5].
The concept of therapeutic vaccines relies on the fact that the
activation of immunological mechanisms leading to cytotoxic
responses, particularly antigen-specific CD8+ T cell activation,
permanently eradicates virus-infected or tumor cells [6]. Although
theoretically sound and technologically feasible, the development
of vaccines that efficiently activate antigen-specific CD8+ T cell
populations to control the replication of viruses, such as HIV,
remains elusive, as dramatically illustrated by the STEP program
[7]. Similarly, numerous attempts to develop both prophylactic
and therapeutic anti-HSV vaccines have systematically failed, and
new insights regarding the immunological control of HSV-1 and
HSV-2 infections are eagerly awaited [8,9]. Vaccines targeting the
tumors induced by HPV, under both experimental and clinical
conditions, stand as the best and most promising examples of the
viability of therapeutic vaccines as immunological tools for the
control of infectious and degenerative diseases [10–15].
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DNA vaccines have been widely used as therapies against
tumors and viruses because of their capability to induce antigen-
specific CD8+ T cell responses as well as their rather simple
manipulation [16,17]. DNA vaccines are also amenable to the
development of multivalent formulations either by a mixture of
plasmids encoding single antigens or by multiple antigens
expressed as fused epitopes [18] or proteins derived from the
same or different pathogens [19–21]. Multivalent DNA vectors
can also be engineered to encode polycistronic transcripts under
the control of a single promoter, leading to the simultaneous
expression of multiple antigens in transfected host cells [22–26].
We have previously shown that DNA vaccines encoding the
HPV-16 E7 oncoprotein genetically fused to HSV-1 glycoprotein
D (gD) enhance both the induction of E7-specific CD8+ T cell
responses and therapeutic/prophylactic anti-tumor effects com-
pared to vaccines encoding the non-fused HPV oncoproteins in
mice [15,27,28]. Additional evidence has indicated that these gD-
dependent immunological effects, particularly the activation of
CD8+ T cell responses to bystander antigens, involve the binding
of gD to herpes virus entry mediator (HVEM) and the blockage of
a co-inhibitory immune mechanism involving the B- and T-
lymphocyte attenuator (BTLA) cell receptor [13,29]. In addition,
further experimental evidence has indicated that the binding of gD
to HVEM not only represents an important step in virus entry but
also triggers an NF-kB-activation pathway and inhibits apoptosis
in HVEM-expressing cells, such as antigen-presenting cells
[30,31].
More recently, the fusion of gD with the influenza virus
nucleoprotein further demonstrated that an adjuvant effect on
CD8+ T cell responses can be achieved with different antigens and
reveals the possibility of the development of multivalent anti-virus
vaccine formulations that are able to induce prophylactic and/or
therapeutic protective immune responses [32]. In the present
study, we applied this vaccine technology to develop trivalent
DNA vaccines encoding the HSV-1 protein gD genetically fused
with both the HPV-16 oncoprotein E7 and the HIV-1 protein p24
by the same transfected cell. To achieve the simultaneous
expression of the two hybrid proteins using a single vaccine
vector, we employed a bicistronic expression system using an
internal ribosome entry site (IRES) sequence [23,24]. Two vaccine
vectors were constructed, pIRES I and pIRES II, which expressed
the recombinant hybrid proteins under the control of a strong
virus promoter (CMV) but differed in the order of the cistrons with
respect to the promoter. Mammalian cells transfected with the
recombinant vectors simultaneously expressed the HSV, HIV and
HPV proteins at the cell surface. More importantly, C57BL/6 or
BALB/c mice immunized with the tested vaccines elicited antigen-
specific CD8+ T cell responses and were protected to challenges
with a vaccinia virus expressing the HIV-1 protein Gag and a
HSV-1 strain. In addition, vaccine administration could thera-
peutically eradicate the growth of tumor cells expressing the HPV-
16 oncoproteins implanted in C57BL/6 mice. Altogether, the
present study demonstrates that the generation of a trivalent HIV,
HSV and HPV anti-cancer vaccine is a feasible goal and should be
pursued as a potential tool to prevent and/or treat infections with
these viruses.
Results
Generation of Trivalent DNA Vaccines that
Simultaneously Encode HIV, HSV and HPV Antigens
The DNA vaccines tested in this study were obtained by
amplifying the chimeric HPV-16 E7 or HIV-1 p24 coding
sequences, both of which were fused to the HSV-1 gD sequence,
and cloning them into the pIRES vector. This process generated
two bifunctional plasmids, pIRES I and pIRES II, which only
differ in the order of their cloned chimeric genes (Figure 1A).
pIRES I carries the gDp24 gene fusion upstream of the IRES
sequence and the gDE7 gene fusion downstream of this regulatory
sequence. In contrast, the pIRES II vector carries the gDE7 and
gDp24 sequences upstream and downstream of the IRES
sequence, respectively. To confirm the expression and cellular
localization of the encoded hybrid proteins, the recombinant DNA
vaccines were introduced into mammalian COS-7 cells, and the
encoded proteins were observed by immunofluorescence. The
HSV-1 protein gD is a viral envelope glycoprotein that is
expressed on the surface of infected cells via a C-terminal anchor
sequence [33]. Thus, the recombinant proteins were detected in
non-permeabilized cells treated with specific monoclonal (gD) or
polyclonal (p24 and E7) antibodies against the target antigens.
Cells transfected with pIRES I or pIRES II were simultaneously
stained with antibodies against all three viral antigens (Figure 1B).
Signals corresponding to the three proteins were detected mainly
at the surface of the non-permeabilized cells. These results indicate
that the hybrid proteins were correctly folded and properly
targeted to the cell membrane compartment of the pIRES I- and
pIRES II-transfected cells.
pIRES I and pIRES II Vaccination Induces the Activation of
Antigen-specific CD8+ T Cells and Simultaneous
Protective Responses against Gag-expressing Vaccinia
Virus and Tumor Cells Expressing HPV-16 Antigens
Mice were immunized with pIRES I and pIRES II and
monitored for the activation of E7-specific (in C57BL/6 mice) and
p24-specific (in BALB/c mice) CD8+ T cells, the key immuno-
logical response required for both the control of virus-induced
tumors and intracellularly replicating viruses. The CD8+ T cell
mediated responses were first monitored in the vaccinated mice by
detecting the level of antigen-specific IFN-c+ -producing CD8+ T
cells using both ICS and ELISPOT assays for total spleen cells
harvested fourteen days after the last immunization dose. The cells
harvested from the vaccinated mice were incubated with synthetic
peptides corresponding to the immunodominant HPV-16 E7 and
HIV-1 p24 MHC-I-restricted CD8+ T cell-specific epitopes for the
H-2Kb and H-2Kd haplotypes, respectively. Cells stimulated with
the H-2Kd-restricted p24 peptide for 6 h resulted in the activation
of p24-specific IFN-c+/CD8+ T cells at frequencies of approxi-
mately 1% and 0.6% in BALB/c mice immunized with pIRES I
and pIRES II, respectively, as determined by ICS (Figure 2A).
Following the same stimulation procedure with the p24-specific
peptide but evaluating the results with an ELISPOT assay, only
the animals vaccinated with pIRES I reached a statistically higher
response compared with the control group immunized with the
empty DNA vector (Figure 2B). The E7-specific IFN-c+/CD8+ T
cell responses elicited in the vaccinated C57BL/6 mice were
determined using the H-2Kb-restricted E7-specific peptide.
Intracellular IFN-c staining showed that the animals immunized
with pIRES I or pIRES II developed higher E7-specific IFN-c+/
CD8+ cell responses compared with mice immunized with the
control vector, while only the animals immunized with the pIRES
II vector generated positive responses compared with the control
group when the responses were analyzed with the ELISPOT assay
(Figure 2C and D). In addition, the E7-specific responses
detected in the mice immunized with pIRES II were statistically
higher than those detected in the mice immunized with pIRES I,
as monitored by ICS (Figure 2C). Collectively, these results
indicate that immunization with pIRES I and pIRES II induces
Trivalent HIV, HSV and Anti-Tumor HPV Vaccines
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p24- and E7-specific CD8+ T cell responses in mice, but higher
E7-specific IFN-c+/CD8+ T cell responses are present in mice
immunized with the vector in which the E7/gD fusion is encoded
by the first cistron (pIRES II).
To further demonstrate that the antigen-specific activation of
CD8+ T cells was functional in the vaccinated mice, we measured
the in vivo antigen-specific cytotoxic responses elicited in mice
immunized with pIRES I or pIRES II. Splenocytes harvested from
non-vaccinated mice were surface labeled with both a fluorescent
label (CFSE) and either the MHC-I restricted p24- or E7-specific
peptide. The labeled cells were intravenously introduced into
vaccinated mice, which were monitored 24 h later for the specific
lysis of the labeled cells in their spleens. The relative reduction in
the level of peptide-labeled cells compared with cells labeled only
with CFSE was indicative of antigen-specific CD8+ T cell-
dependent cytolytic activity. Mice immunized with pIRES I
mounted a p24-specific CD8+ T cell-dependent cytotoxic
response, while mice immunized with pIRES II showed a
statistically significant E7-specific CD8+ T cell-dependent cyto-
toxic response compared with mice immunized with the empty
vector (Figure 3A and B). These results further demonstrate that
effective antigen-specific CD8+ T cell-dependent cytotoxic re-
sponses are induced by the vaccines in which the target gene is
expressed by the first cistron of the bicistronic transcript.
As a final step to evaluate the protective immunological status of
the mice immunized with the DNA vaccines encoding the HPV
Figure 1. Construction of bicistronic DNA vaccines encoding HPV, HIV and HSV antigens for expression in mammalian cells. (A)
Schematic linear representation of the trivalent DNA vaccines. pIRES I and pIRES II contain gDp24 and gDE7 chimeric gene fusions, which are inverted
with regard to the CMV promoter and IRES sequence. The empty vector pIRES Ø was used as a control. The nucleotide numbers corresponding to the
IRES sequence and the cloned chimeric genes are indicated. (B) In vitro expression of the chimeric proteins encoded by pIRES I (left panels) and pIRES
II (right panels). Non-permeabilized pIRES I- or pIRES II-transfected COS-7 cells were labeled with antigen-specific antibodies for the simultaneous
detection of the HSV-1 protein gD and the HIV-1 protein p24 or the HPV-16 oncoprotein E7. Green, gD; red, p24 or E7; yellow, co-localization of gD
with p24 or E7; blue, DAPI nuclear staining.
doi:10.1371/journal.pone.0071322.g001
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and HIV antigens, we submitted the vaccinated mice to challenges
with a recombinant vaccinia virus expressing the Gag protein or
TC-1 tumor cells expressing the HPV-16 E6 and E7 oncoproteins.
As shown in Figure 3C, female BALB/c mice immunized with
pIRES I or pIRES II showed significantly less of the recombinant
vaccinia virus in their ovaries after challenge with the vAbT141
vaccinia strain (1,000- or 100-fold less compared with the control
group immunized with the empty DNA vector, respectively).
Similarly, C57BL/6 mice immunized with pIRES I or pIRES II
developed protective anti-tumor immunity. All mice challenged
two weeks after immunization with pIRES II remained tumor free,
while 60% of the mice immunized with pIRES I remained tumor-
free after transplantation of the TC-1 cells (Figure 3D). Notably,
mice immunized with the DNA vaccines developed partial
therapeutic anti-tumor immunity. Twenty percent of C57BL/
6 mice transplanted with TC-1 cells and subsequently treated with
three doses pIRES I remained tumor-free, while 60% of the mice
immunized with pIRES II developed a therapeutic anti-tumor
response, as they were able to eradicate the TC-1 cells that were
previously transplanted into their bodies (Figure 3E). Collective-
ly, these results indicate that the DNA vaccines are able to induce
functional and protective CD8+ T cell-dependent responses in
vaccinated mice, leading to efficient anti-virus (HIV) and anti-
tumor (HPV) effects. In addition, these results indicate that
vaccination with these DNA vectors, particularly pIRES II,
confers therapeutic immune responses to tumor cells.
Vaccination with pIRES I or pIRES II Induces gD-specific T
Cell Responses and Resistance to HSV-1 Challenges
The trivalent nature of the immune responses elicited in the
mice immunized with pIRES I or pIRES II was confirmed after
determination of the HSV gD-specific T cell responses. Two weeks
after the last immunization dose, BALB/c mice were monitored
for the induction of gD-specific CD4+ and CD8+ T cell responses
using ELISPOT assays. As shown in Figure 4A, mice vaccinated
with pIRES I or pIRES II developed similar antigen-specific
cellular responses, as measured by the number of IFN-c-secreting
cells after stimulation with purified gD, compared with mice
immunized with the empty vector. Analysis of the activated
antigen-specific T cell populations by flow cytometry indicated
that both pIRES I and pIRES II activated the CD4+ and CD8+ T
cells. Nonetheless, the mice immunized with pIRES II activated a
higher proportion of gD-specific IFN-c producing CD8+ T cells
Figure 2. Activation of antigen-specific IFN-c-producing CD8+ T cell precursors in mice immunized with pIRES I or pIRES II. (A-B)
Spleen cells from BALB/c mice spleen cells were stimulated with the MHC-I-restricted p24-specific peptide, and the p24-specific IFN-c-producing
CD8+ T cells were detected by intracellular cytokine staining (A) or ELISPOT assay (B). (C–D) Spleen cells from C57BL/6 mice were stimulated with the
MHC-I-restricted E7-specific peptide, and the E7-specific IFN-c-producing CD8+ T cells were detected by IFN-c intracellular staining (C) or ELISPOT
assay (D). Mice were i.m. immunized with three doses of the DNA vaccines with one week intervals between doses (100 mg/dose). The CD8+ T-cell
responses were analyzed two weeks after the last dose. *p,0.05. Data represent the compilation of two independent experiments with four mice per
immunization group (n = 8) and results expressed by each animal analyzed. pIRES is the empty vector used as immunization control.
doi:10.1371/journal.pone.0071322.g002
Trivalent HIV, HSV and Anti-Tumor HPV Vaccines
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Figure 3. Induction of in vivo E7- and p24-specific cytolytic CD8+ T cell responses in immunized mice. (A–B) In vivo antigen-specific CD8+
T cell-dependent cytotoxic responses in the vaccinated mice was measured two weeks after the last immunization dose. Spleen cells from BALB/c or
C57BL/6 mice were labeled with CFSE and pulsed with synthetic peptides representing the immunodominant MHC-I-restricted epitopes of p24 (A) or
E7 (B). Data shown in A and B represent the compilation of two independent experiments, encompassing four and five mice per group (n = 9) with
results based on the response of each animal. (C) The protective immunity elicited in BALB/c mice immunized with pIRES I or pIRES II was measured
after challenge with a recombinant vaccinia virus expressing the HIV-1 protein Gag. Female BALB/c mice were challenged with 26106 P.F.U. of rVV-
Gag, and 5 days later, the level of viable vaccinia virus in the ovaries was determined after titration in Vero cells. Data shown in C represent the
compilation of two independent experiments carried out with pooled samples from five mice per group. *p,0.05. (D) Prophylactic and (E)
therapeutic anti-tumor immunity in C57BL/6 mice immunized with pIRES I or PIRES II. The prophylactic anti-tumor effects were determined in five
vaccinated female mice after the s.c. transplantation of 7.56104 TC-1 cells two weeks after the last vaccination. The therapeutic anti-tumor effects
induced by the vaccines were determined after transplantation of 7.56104 TC-1 cells one day before the administration of the first vaccine dose. Data
shown in D and E represent the compilation of two independent experiments, with five mice per group. The survival curves D and E raised p values of
0.0001 and 0.0006, respectively, in the Logrank test for trend. pIRES is the empty vector used as immunization control.
doi:10.1371/journal.pone.0071322.g003
Trivalent HIV, HSV and Anti-Tumor HPV Vaccines
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(CD8+/CD4+ ratio of 1.2) than mice immunized with pIRES I
(CD8+/CD4+ ratio of 0.64) (Figure 4B). pIRES I- and pIRES II-
vaccinated mice were also partially protected against lethal
challenge with HSV-1. Sixty percent of the BALB/c mice
immunized with pIRES II survived the lethal challenge carried
out with HSV-1 EK strains, while a lower level of protection
(30%) was achieved in mice immunized with pIRES I (Figure 4C).
In conclusion, these results also confirm that the tested DNA
vaccines induce T cell-dependent immune responses and protec-
tive immunity against HSV.
Materials and Methods
Ethics Statement
All animal handling and immunization procedures were
approved by the institutional ethics committee for animal
experimentation and care ‘‘CEUA ICB-USP – Comissa˜o de E´tica no
Uso de Animais do Instituto de Cieˆncias Biome´dicas da Universidade de Sa˜o
Paulo’’ (protocol number: 12/05/2010-007-82-2) and followed
standard rules approved by the Brazilian College of Animal
Experimentation (COBEA).
Mice, Cell Lines and Antibodies
C57BL/6 and BALB/c mice (6–8 weeks old) were provided by
the animal facility of the Department of Parasitology at the
University of Sa˜o Paulo. The TC-1 tumor cell lineage [34], which
is derived from C57BL/6 mouse lung epithelial cells transformed
with the v-Ha-ras oncogene and HPV-16 E6 and E7, was kindly
provided by Dr T. C. Wu at John Hopkins University. TC-1 and
COS-7 (ATCCH CRL-1651TM) cells were cultured in Dulbeccos
modified Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum (FBS) and 50 units/mL penicillin/streptomycin and
kept at 37uC and 5% CO2. For the tumor challenge experiments,
TC-1 cells were harvested after trypsinization, washed twice, and
suspended in serum-free media at the appropriate concentrations
for injection. Rabbit anti-gD, mouse anti-p24 and mouse anti-E7
polyclonal antibodies were generated in our laboratory by
Figure 4. Induction of gD-specific functional T cell responses in mice immunized with pIRES I or pIRES II. (A) Detection of gD-specific
IFN-c-secreting cells in vaccinated BALB/c mice was performed two weeks after the last immunization dose. Spleen cells from individual mice (n = 8)
were cultured in the presence of full-length recombinant purified gD for 72 h. The frequencies of the gD-specific IFN-c-secreting cells were measured
by ELISPOT. (B) Detection of gD-specific IFN-c-secreting CD8+ and CD4+ T cells in those mice described in (A) with spleen cells previously incubated
for 72 h with the recombinant gD analyzed by flow cytometry. Data shown in A and B represent the compilation of two independent experiments,
with four mice per group (n = 8). *p,0.05. (C) Protective anti-HSV immunity elicited in mice immunized with pIRES I or pIRES II. Vaccinated male
BALB/c mice were challenged intranasal with the HSV-1 strain EK (56104 P.F.U./mouse) two weeks after last vaccine dose and mice survival was
monitored for 40 days. Data shown in C represent the compilation of two independent experiments, with five mice per group (n = 10). p= 0.0009
(Logrank test for trend). pIRES is the empty vector used as immunization control.
doi:10.1371/journal.pone.0071322.g004
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subcutaneous injection of four doses of the specific recombinant
proteins in combination with alum.
Cloning of gDp24 and gDE7 in the pIRES Vector
The gDE7 and gDp24 gene fusions were obtained by PCR
amplification using the plasmids pgDE7 [27] and pgDp24 as
templates, which contain the coding sequences of HPV-16 E7 and
HIV-1 clade B p24, respectively, each fused to the coding
sequence of HSV-1 gD. The inserts were amplified using the
primers gDFwXbaI (59 TAG TCT AGA ATG GGG GGG GCT
GCC GCC AGG 39, XbaI restriction site underlined) and
gDFwNheI (59 TAG GCT AGC ATG GGG GGG GCT GCC
GCC AGG 39, NheI restriction site underlined) for subcloning
upstream of the IRES or the primers gDRvNotI (59 TAG GCG
GCC GCG CAC CCA TTA AGG GGG GGT ATC 39, NotI
restriction site underlined) and gDRvEcoRI (59 TAG GAA TTC
GCA CCC ATT AAG GGG GGG TAT C 39, EcoRI restriction
site underlined) for subcloning downstream of the IRES. The
amplicons were cloned into the pGEMTM cloning vector and then
double digested with NheI/EcoRI or XbaI/NotI (Invitrogen,
Carlsbad, CA). The resulting fragments were subcloned into the
pIRESTM vector (Clontech, Mountain View, CA). The plasmid
containing the gDp24 gene fusion upstream of the IRES and
gDE7 downstream of the IRES was named pIRES I. The plasmid
containing the gDE7 gene fusion upstream of the IRES and
gDp24 downstream of the IRES was named pIRES II. All plasmid
constructs were confirmed by automatic DNA sequencing. The
final vectors were propagated in Escherichia coli DH5-a in LB
medium supplemented with ampicillin (100 mg/mL) and purified
using a Qiagen Plasmid Mega Kit (Qiagen, Hilden, Germany).
Cell Transfection and Immunofluorescence Analysis
COS-7 cells were cultivated in 12-well culture plates at an initial
concentration of 26105 cells/well in DMEM supplemented with
10% FBS. On the following day, the cells were transfected using
LipofectamineTM 2000 (Invitrogen) according to the manufactur-
ers instructions. After 36 h, the cells were harvested with PBS
containing 2 mM EDTA, pelleted and incubated with blocking
solution (1% bovine serum albumin in PBS) for 20 min at room
temperature. The cells were washed twice with PBS and then
incubated for 45 min with a 1:100 dilution of a rabbit specific anti-
gD serum and a mouse specific anti-E7 serum or the same anti-gD
serum combined with a mouse specific anti-p24 serum. The cells
were washed twice with PBS and then incubated for 45 min with a
1:200 dilution of FITC-labeled goat anti-mouse IgG (Sigma) or a
1:200 dilution of Texas Red-labeled goat anti-rabbit IgG (Sigma).
The cells were washed twice with PBS, stained with a 1:1,000
dilution of DAPI (1 mg/mL) and visualized for immunofluores-
cence using an inverted microscope (Axiovert model S100, Zeiss)
equipped with a digital camera (Hamamatsu model C5810, Sanyo
Denki).
DNA Vaccination and in vivo Protection Experiments
BALB/c or C57BL/6 mice were intramuscularly (i.m.) immu-
nized with 3 doses of the DNA vaccines at weekly intervals, with
100 mg DNA/dose in PBS in a final volume of 100 mL. Tumor
growth prevention was determined after subcutaneous transplan-
tation of 7.56104 TC-1 cells/mouse in the right flank two weeks
after the last immunization. Therapeutic anti-tumor effects were
measured after transplantation of the TC-1 cells and administra-
tion of ththe first vaccine dose one day later. Tumor growth was
monitored by visual inspection and palpation twice per week over
an observation period of 60 days. The prophylactic anti-HSV
effects in the vaccinated BALB/c mice were determined using the
HSV-1 EK strain (kindly provided by Dr. Erna Geessien Kroon of
the Universidade Federal de Minas Gerais), which was diluted in
PBS, and 10-mL aliquots (containing 56104 P.F.U./dose) were
delivered in the mouse nostrils 15 days after the last immunization
dose. The challenged mice were monitored for survival for
40 days.
To evaluate the prophylactic anti-HIV immune response
induced by the vaccines, mice were challenged with recombinant
vaccinia virus expressing the HIV-1 protein Gag (rVV-Gag),
which was supplied by the NIH (vaccinia strain vABT-141).
Challenge experiments were performed by i.p. inoculating female
BALB/c mice with 26106 P.F.U. of rVV-Gag in 100 mL of saline
two weeks after the last immunization. The mice were euthanized,
and their ovaries were harvested and macerated with a syringe
plunger in 1 mL DMEM. The suspensions were submitted to 2-
fold serial dilution, 100 mL of each dilution was incubated with
Vero cells for 1 h, and the medium was replaced. After 72 h, the
cells were stained with a solution containing 20% alcohol and
0.2% of violet crystal, and subsequently inspected for the viral
plaques.
Determination of CD8+/IFN-c+ T Cell Response by
Intracellular Cytokine Staining (ICS) and ELISPOT Assays
Spleen cells were harvested two weeks after the last immuni-
zation dose, suspended in RPMI 1640 supplemented with 5% SFB
and treated with ACK lysing buffer for 5 min on ice to eliminate
the red blood cells. For intracellular IFN-c staining, spleen cells
(36106 cells/well) were cultured at 37uC in 96-well round-bottom
microtiter plates (BD Biosciences) in 200 mL of RPMI 1640
medium supplemented with penicillin (100 U/mL), streptomycin
(100 mg/mL), 2-ME (50 mM), L-glutamine (2 mM), sodium
pyruvate (1 mM), 10% heat-inactivated FBS and brefeldin A
(GolgiPlug, BD Biosciences) at a final concentration of 10 mg/mL.
In vitro stimulation was achieved using the MHC-I-restricted (H-
2Kb) E7-specific peptide (E749–57; RAHYNIVTF) or the MHC-I-
restricted (H-2Kd) p24-specific peptide (gag197–205; AMQMLK-
ETI) at a concentration of 3 mg/mL for 6 h or recombinant gD at
a concentration of 10 mg/mL for 72 h (brefeldin A was added in
the last 6 h of culture). The cells were incubated for 30 min at 4uC
with 100 mL of a 1:100 dilution of FITC-conjugated mAb anti-
mouse CD8a and Pe-Cy5-conjugated mAb anti-mouse CD4 (BD
Biosciences), washed with PBS containing 2% FBS, fixed with 4%
paraformaldehyde for 20 min and then permeabilized with 0.5%
saponin for 20 min at 4uC. After washing, the cells were incubated
for 30 min at 4uC with a 1:100 dilution of PE-labeled mAb anti-
mouse IFN-c (BD Biosciences). The cells were examined with a
FACSCaliburTM cytometer (BD Biosciences), and the data were
analyzed using FlowJo software (Tree Star). ELISPOT assays were
carried out after the incubation of splenocytes with the same
stimuli used in the ICS assay but for 24 hours for peptide
stimulation and 72 hours for protein stimulation. Spleen cells
(56105/well) were seeded for in vitro stimulation in nitrocellulose-
bottom plates that were previously coated with anti-IFN-c. IFN-c
secretion was detected after staining with a biotinylated anti-IFN-c
antibody overnight at 4uC and treatment with the AEC Substrate
Set (BD Biosciences) according to manufacturer’s instructions.
In vivo Antigen-specific Cytotoxicity Assays
Naı¨ve mouse splenocytes were stained with 0.5 mM or 5 mM of
carboxy fluorescein diacetate succinimidyl ester (CFSE) (Invitro-
gen). The cells labeled with 5 mM CFSE were pulsed with 2.5 mg/
mL of the E7-specific peptide (RAHYNIVTF) or the p24-specific
(AMQMLKETI) peptide for 40 min at 37uC. Equal amounts of
both cell populations (26107 cells) were intravenously (i.v.)
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inoculated into C57BL/6 or BALB/c mice, for determination of
anti-E7 or anti-p24 responses, respectively, that were previously
submitted to the immunization regimens two weeks after the last
immunization dose. One day later, the spleens of the inoculated
mice were harvested and monitored by flow cytometry. The
percentage of target cell killing by specific cytotoxic CD8+ T
lymphocytes (CTL) was determined as previously described [35].
Statistical Analyses
All data, which are expressed as means 6 SD, are represen-
tative of at least five mice per group, and all experiments were
repeated twice. One-way ANOVA followed by Bonferroni’s post-
test was employed whenever individual data points were
compared. The survival and tumor development curves were
submitted to log-rank tests. Differences with p#0.05 were
considered to be statistically significant.
Discussion
The three most relevant viral pathogens associated with sexually
transmitted diseases, HIV, HSV and HPV, share common
features, such as mucosal transmission, the ability to establish
chronic infections, and the requirement of antigen-specific
cytotoxic CD8+ T cell activation for the efficient control of
intracellular virus replication. So far the search for vaccines against
these pathogens has emphasized strategies involving the induction
of antibodies that are able to neutralize the viruses. Indeed, such
approaches have been successful, as two preventive and lucrative
anti-HPV vaccines have been generated and are currently being
used in several countries [3,4]. Nonetheless, there is a strong belief
that the immunological control of HIV and HSV as well as the
tumors induced by HPV, either prophylactic or therapeutically,
will require the implementation of alternative methodological
tools. In the present study, we propose a trivalent vaccine
approach in which bicistronic DNA vaccines simultaneously
encoding antigens of HIV, HSV and HPV activate antigen-
specific and functionally active CD8+ T cell responses under
experimental conditions. Moreover, our study demonstrates that
the tested vaccine formulations confer protective immunity to all
three antigens from HIV, HPV and HSV viruses, as observed in
mice challenged with an HSV-1 strain or a recombinant vaccinia
virus encoding the HIV-1 protein Gag and in mice implanted with
tumor cells expressing the HPV-16 oncoproteins. Altogether, our
results indicate that the development of multivalent vaccines
inducing protective immunity against HIV, HSV and HPV are
feasible and further support the relevance of cytotoxic T cell
responses for the protective immunity to these pathogens.
Our proposed vaccine strategy is based on two methodological
approaches that induce protective immunity. First, the use of
bicistronic DNA vectors that allow for the simultaneous expression
of two chimeric proteins (HIV-1 p24 and HPV-16 E7 that are
both genetically fused to the HSV-1 envelope protein) gD in the
same transfected cells permits a more balanced and efficient
induction of CD8+ T cell responses in vaccinated subjects. Second,
chimeric proteins in which both the HIV-1 protein p24 and the
HPV-16 oncoprotein E7 are fused to the HSV-1 protein gD at its
C-terminus are targeted to the surface of the transfected cells. In
particular, this second feature results in the induction of gD-
specific immunomodulatory pathways and the subsequent en-
hanced activation of CD8+ T cell responses to the encoded
antigens and, therefore, to the protective immunity generated in
the vaccinated animals [15,32,36]. The rationale behind the use of
DNA vaccine vectors is well established and includes the potential
to activate cellular immune responses without the use of exogenous
adjuvants, the lack of interference from previously established
immunity, an excellent safety record and a rather simple and low-
cost production pipeline [37]. Characteristically, DNA vectors, like
most eukaryotic genes, are monocistronic, with a single structural
gene under the control of a promoter. The discovery of IRES
sequences revealed the possibility of generating polycistronic DNA
vectors, leading to the simultaneous activation of immune
responses to different antigens without the need to transfect cells
several plasmids [23,24,38,39]. Our results confirmed that both of
our DNA vectors constructed with this IRES technology promoted
the synthesis of the target antigens in the same transfected cell. In
addition, immunization of mice with pIRES I or pIRES II elicited
antigen-specific CD8+ T cell responses and in vivo cytotoxic
responses. These results may reflect the differential expression of
the antigens encoded by the two cistrons, with higher expression
for the proximal genes compared with the distal cistron. Similar
effects have been previously reported by other groups [24,25,40],
and most likely reflect premature transcript termination at the
IRES sequence, which reduces the level of full-length mRNA and,
consequently, the amount of the protein encoded by the second
cistron. Induction of a more balanced immune response to the
target antigens could, thus, be achieved after the concomitant
administration of both pIRES I and II vectors. Nonetheless, the
present results indicate that the bicistronic expression technology
still needs further improvement in order to be successfully used at
in vivo situations, particularly, as vaccines.
The efficient activation of T cell responses involves the correct
processing and surface presentation of epitopes by APCs and the
correct signaling between APCs and effector T cells, which is
mediated by surface-exposed receptors, by means of different co-
stimulatory and co-inhibitory pathways [41,42]. The HSV-1
protein gD encoded by our DNA vaccines plays dual roles in the
induction of protective anti-viral responses. First, it acts as a highly
conserved protective antigen for both the HSV-1 and HSV-2
strains, and second, it exerts strong and complex immunomodu-
latory effects, enhancing the activation of the CD8+ T cell
response to its genetically fused antigens [29,43]. The entry of both
HSV-1 and HSV-2 into the host cell is mediated, at least in part,
by the specific interaction between gD and HVEM, a member of
the TNFR family [44]. In addition, the binding of gD to HVEM
blocks the co-inhibitory pathway by competing with BTLA and
CD160 [43]. In contrast, the binding of gD does not interfere with
the co-stimulatory functions of HVEM, which involve other
surface proteins, such as LIGHT and lymphotoxin-a, and lead to
the stimulation of the transcription factors NF-kb and AP-1 and
the subsequent activation and differentiation of effector T cells
[45,46]. Further experimental evidence has demonstrated that the
binding of gD to HVEM activates the NF-kb-dependent signaling
pathway irrespective of additional HVEM-binding factors [30,31].
Previous results, based both on DNA vaccines and adenovirus
vectors, have demonstrated that the fusion of heterologous
sequences at the C-terminus of gD target the protein to the outer
face of the cytoplasmic membrane where the binding to HVEM
occurs, leading to the enhanced activation of CD8+ T cell
responses to the heterologous antigen [13,15,32,36]. Similar but
less significant results have also been obtained with recombinant
purified proteins [14], further suggesting that endogenous
expression and membrane localization contributes to the gD-
mediated CD8+ T cell adjuvant effects.
Induction of cytotoxic CD8+ T cell responses represents an
important immunological correlate for vaccines aiming therapeu-
tic activation of protective immunity, such as those involved with
eradication of chronic infections and cancer [47,48]. Indeed,
cytotoxic CD8+ T cells are involved in the resolution of infections
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with HIV [49–51], HSV [52,53] and HPV-induced tumors
[15,27,54]. The present study demonstrated that bicistronic DNA
vaccines encoding gD fused antigens could enhance the induction
of antigen-specific cytotoxic CD8+ T cell responses and confer
protective immunity to virus infection and therapeutic control of
tumor growth. These findings also indicate that a trivalent vaccine
formulation targeting HIV, HSV and HPV associated cancer is a
feasible goal and represent an interesting approach to be tested in
the near future.
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